miR-210 promotes IPF fibroblast proliferation in response to hypoxia

American Journal of Physiology - Lung Cellular and Molecular Physiology

Volumn 307, Issue 4, 2014, Pages

  Bodempudi, Vidya ^a   Hergert, Polla ^a   Smith, Karen ^a   Xia, Hong ^a   Herrera, Jeremy ^a   Peterson, Mark ^a   Khalil, Wajahat ^a   Kahm, Judy ^a   Bitterman, Peter B ^a   Henke, Craig A ^a  

^a UNIVERSITY OF MINNESOTA   (United States)

Author keywords

Fibroblast proliferation; Hypoxia; Idiopathic pulmonary fibrosis; miR 210

Indexed keywords

CARBONATE DEHYDRATASE IX; HYPOXIA INDUCIBLE FACTOR 2ALPHA; MICRORNA 210; MNT; PROTEIN INHIBITOR; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CELL PROLIFERATION; CONTROLLED STUDY; DISEASE ASSOCIATION; FIBROSING ALVEOLITIS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; HYPOXIA; HYPOXIC CELL; LUNG FIBROBLAST; LUNG PARENCHYMA; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN TARGETING; RETICULUM CELL; TISSUE CULTURE;

FIBROBLAST PROLIFERATION; HYPOXIA; IDIOPATHIC PULMONARY FIBROSIS; MIR-210;

ANOXIA; BASIC HELIX-LOOP-HELIX LEUCINE ZIPPER TRANSCRIPTION FACTORS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CELL LINE; CELL PROLIFERATION; DISEASE PROGRESSION; FIBROBLASTS; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; LUNG; MICRORNAS; REPRESSOR PROTEINS;

EID: 84906078197     PISSN: 10400605     EISSN: 15221504     Source Type: Journal    
DOI: 10.1152/ajplung.00069.2014     Document Type: Article

References (55)

1. American Thoracic Society. Idiopathic pulmonary fibrosis: diagnosis and treatment. International consensus statement American Thoracic Society (ATS), and the European Respiratory Society (ERS). Am J Respir Crit Care Med 161: 646-664, 2000.
2. Basset F, Ferrans VJ, Soler P, Takemura T, Fukuda Y, Crystal RG. Intraluminal fibrosis in interstitial lung disorders. Am J Pathol 122: 443-461, 1986.
3. Biswas S, Roy S, Banerjee J, Hussain S, Khanna S, Meenakshisundarm G, Kuppusamy P, Friedman A, Sen CK. Hypoxia inducible microRNA 210 attenuates keratinocyte proliferation and impairs closure in a murine model of ischemic wounds. Proc Natl Acad Sci USA 107: 6976-6981, 2010.
4. Bradley TR, Hodgson GS, Rosendaal M. The effect of oxygen tension on haemopoietic and fibroblast cell proliferation in vitro. J Cell Physiol 97: 517-522, 1978.
5. Camps C, Buffa FM, Colella S, Moore J, Sotiriou C, Sheldon H, Harris AL, Gleadle JM, Raqoussis J. has-miR-210 is induced by hypoxia and is an independent prognostic factor in breast cancer. Clin Cancer Res 14: 1340-1348, 2008.
6. Carreau A, El Hafny-Rahbi B, Matejuk A, Grillon C, Kieda C. Why is the partial oxygen pressure of human tissues a crucial parameter? Small molecules and hypoxia. J Cell Mol Med 15: 1239-1253, 2011.
7. Chan SY, Loscalzo J. MicroRNA210. A unique and pleiotropic hypoxamir. Cell Cycle 9: 1072-1083, 2010.
8. Chen B, Polunovsky V, White J, Blazar B, Nakhleh R, Jessurun J, Peterson M, Bitterman P. Mesenchymal cells isolated after acute lung injury manifest an enhanced proliferative phenotype. J Clin Invest 90: 1778-1785, 1992.
9. Cool CD, Groshong SD, Rai PR, Henson PM, Stewart JS, Brown KK. Fibroblast foci are not discrete sites of lung injury or repair: the fibroblast reticulum. Am J Respir Crit Care Med 174: 654-658, 2006.
10. Coultas DB, Zumwalt RE, Black WC, Sobonya RE. The epidemiology of interstitial lung diseases. Am J Respir Crit Care Med 150: 967-972, 1994.
11. DeGregori LG, Yan Z, Jakoi L, Ishida S, Williams RS, Nevins JR. E2F3 activity is regulated during the cell cycle and is required for the induction of S phase. Genes Dev 12: 2120-2130, 1998.
12. Evans SM, Koch CJ. Prognostic significance of tumor oxygenation in humans. Cancer Lett 195: 1-16, 2003.
13. Fasanaro P, Alessandra YD, Di Stefano V, Melchionna R, Romani S, Pompilio G, Capogrossi MC, Martelli F. MicroRNA-210 modulates endothelial cell response to hypoxia and inhibits the receptor tyrosine kinase ligand ephrin-A3. J Biol Chem 283: 15878-15883, 2008.
14. Fasanaro P, Greco S, Lorenzi M, Pescatori M, Brioschi M, Kulshreshtha R, Banfi C, Stubbs A, Calin GA, Ivan M, Capogrossi MC, Martelli F. An integrated approach for experimental target identification of hypoxia-induced miR-210. J Biol Chem 284: 35134-35143, 2009.
15. Ferencz N, Nardone RM. A non-continuous flow gas chamber for the cultivation of mammalian cells grown in petri dishes. Exp Cell Res 53: 139-144, 1968.
16. Fisher AR. Some effects of different oxygen tensions of oxygen on the respiration and growth of L-strain fibroblasts. Nature 186: 315-216, 1960.
17. Flaherty KR, Andrei AC, Murray S, Fraley C, Colby TV, Travis WD, Lama V, Kazerooni EA, Gross BH, Toews GB, Martinez FJ. Idiopathic pulmonary fibrosis. Prognositc value of changes in physiology and sixminute walk test. Am J Respir Crit Care Med 174: 803-809, 2006.
18. Fukuda Y, Ishizaki M, Masuda Y, Kimura G, Kawanami O, Masugi Y. The role of intraalveolar fibrosis in the process of pulmonary structural remodeling in patients with diffuse alveolar damage. Am J Pathol 126: 171-182, 1987.
19. Giannakakis A, Huang J, Greshock J, Liang S, Dionyssios K, Weber BL, Sandaltzopoulos R, Simon C, Coukos G, Zhang L. miR-210 links hypoxia with cell cycle regulation and is deleted in human epithelial ovarian cancer. Cancer Biol Ther 7: 255-264, 2008.
20. Guyton AC, Hall JE. Physical principles of gas exchange; diffusion of oxygen and carbon dioxide through the respiratory membrane. In: Textbook of Medical Physiology, 10th edition. Philadelphia, PA: W. B. Saunders, 2000, p. 454.
21. Halberg N, Khan T, Trujillo ME, Wernstedt-Asterholm I, Attie AD, Sherwani S, Wang ZV, Landskroner-Eiger S, Dineen S, Magalang U, Brekken RA, Scherer PE. Hypoxia-inducible factor 1α induces fibrosis and insulin resistance in white adipose tissue. Mol Cell Biol 29: 4467-4483, 2009.
22. Harris AL. Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2: 38-47, 2002.
23. Higgins DF, Kimura K, Bernhardt WM, Shrimanker N, Akai Y, Hohenstein B, Saito Y, Johnson RS, Kretzler M, Cohen CD, Eckardt KU, Iwano M, Haase VH. Hypoxia promotes fibrogenesis in vivo via HIF-1 stimulation of epithelial-to-mesenchymal transition. J Clin Invest 117: 3810-3820, 2007.
24. Hu S, Huang M, Li Z, Jia F, Ghosh Z, Lijkwan MA, Fasanaro P, Sun N, Wang X, Martelli F, Robbins RC, Wu JC. MicroRNA-210 as a novel therapy for treatment of ischemic heart disease. Circulation 122: S124-S131, 2010.
25. Huang LE, Bunn HF. Hypoxia-inducible factor and its biomedical relevance. J Biol Chem 278: 19575-19578, 2003.
26. Huang X, Ding L, Bennewith KL, Tong RT, Welford SM, Ang KK, Story M, Le QT, Giaccia AJ. Hypoxia-inducible mir-210 regulates normoxic gene expression involved in tumor initiation. Mol Cell 35: 856-867, 2009.
27. Ivanovic Z. Hypoxia or in situ normoxia: the stem cell paradigm. J Cell Physiol 219: 271-275, 2009.
28. Jain M, Sznajder JI. Effects of hypoxia on the alveolar epithelium. Proc Am Thorac Soc 2: 202-205, 2005.
29. Kottmann RM, Kulkami AA, Smolnycki KA, Lyda E, Dahanayake T, Salibi R, Honnons S, Jones C, Isern NG, Hu JZ, Nathan SD, Grant G, Phipps RP, Sime PJ. Lactic acid is elevated in idiopathic pulmonary fibrosis and induces myofibroblast differentiationvia pH-dependent activation of transforming growth factor-β. Am J Respir Crit Care Med 186: 740-751, 2012.
30. Krick S, Eul BG, Hanze J, Savai R, Grimminger F, Seeger W, Rose F. Role of hypoxia-inducible factor-1 alpha in hypoxia-induced apoptosis of primary alveolar epithelial type II cells. Am J Respir Cell Mol Biol 32: 395-403, 2005.
31. Kuhn C 3rd, Boldt J, King TE Jr, Crouch E, Vartio T, McDonald JA. An immunohistochemical study of architectural remodeling and connective tissue synthesis in pulmonary fibrosis. Am Rev Respir Dis 140: 1693-1703, 1989.
32. Kuhn C, McDonald JA. The roles of the myofibroblast in idiopathic pulmonary fibrosis. Ultrastructural and immunohistochemical features of sites of active extracellular matrix synthesis. Am J Pathol 138: 1257-1265, 1991.
33. Larsson O, Diebold D, Fan D, Peterson M, Nho RS, Bitterman PB, Henke CA. Fibrotic myofibroblasts manifest genome-wide derangements of translational control. PLoS One 3: e3220, 2008.
34. Leungwattanakij S, Bivalacqua TJ, Mustafa FU, Yang DY, Hyun JS, Champion HC, Abdel-Mageed AB, Hellstrom WJG. Cavernous neurotomy causes hypoxia and fibrosis in rat corpus cavernosum. J Androl 24: 239-245, 2003.
35. Li Z, Bao S, Wu Q, Wang H, Eyler C, Sathornsumetee S, Shi Q, Cao Y, Lathia J, McLendon RE, Hjelmeland AB, Rich JN. Hypoxiainducible factors regulate tumorigenic capacity of glioma stem cells. Cancer Cell 15: 501-513, 2009.
36. Loncaster JA, Harris AL, Davidson SE. Carbonic anhydrase (CAIX) expression, a potential new intrinsic marker of hypoxia: correlations with tumor oxygen measurements, and prognosis in locally advanced carcinoma of the cervix. Cancer Res 61: 6394-6399, 2001.
37. Mannino DM, Etzel RA, Parrish RG. Pulmonary fibrosis deaths in the United States, 1979-1991. An analysis of multiple-cause mortality data. Am J Respir Crit Care Med 153: 1548-1552, 1996.
38. Masamune A, Kikuta K, Watanabe T, Satoh K, Hirota M, Shimosegawa T. Hypoxia stimulates pancreatic stellate cells to induce fibrosis and angiogenesis in pancreatic cancer. Am J Physiol Gastrointest Liver Physiol 295: G709-G717, 2008.
39. McCormick RI, Blick C, Ragoussis J, Schoedel J, Mole DR, Young AC, Selby PJ, Banks RE, Harris AL. miR-210 is a target of hypoxiainducible factors 1 and 2 in renal cancer, regulates ISCU and correlates with good prognosis. Br J Cancer 108: 1133-1142, 2013.
40. Michailidou Z, Turban S, Miller E, Zou X, Schrader J, Ratcliffe PJ, Hadoke PWF, Walker BR, Iredale JP, Morton NM, Seckl JR. Increased angiogenesis protects against hypoxia and fibrosis in metabolic disease-resistant 11β-hydroxysteroid dehydrogenase type 1 (HSD1)-deficient mice. J Biol Chem 287: 4188-4197, 2012.
41. Mutharasan RK, Nagpal V, Ichikawa Y, Ardehali H. microRNA-210 is upregulated in hypoxic cardiomyocytes through Akt-and p53-dependent pathways and exert cytoprotective effects. Am J Physiol Heart Circ Physiol 301: H1519-H1530, 2011.
42. Noble PW. Idiopathic pulmonary fibrosis: natural history and prognosis. Clin Chest Med 27: S11-S16, 2006.
43. Noble PW, Homer RJ. Idiopathic pulmonary fibrosis: new insights into pathogenesis. Clin Chest Med 25: 749-758, 2004.
44. Oak SR, Murray L, Herath AS, Sleeman M, Anderson I, Joshi AD, Coelho AL, Flaherty KR, Toews GB, Knight D, Martinez FJ, Hogaboam CM. A micro RNA processing defect in rapidly progressing idiopathic pulmonary fibrosis. PLoS One 6: e21253, 2011.
45. Pietras A, Hansford LM, Johnsson AS, Bridges E, Sjolund J, Gisselsson D, Rehn M, Beckman S, Noguera R, Navarro S, Cammenga J, Fredlund E, Kaplan DR, Pahlman S. HIF2+ maintains an undifferentiated state in neural crest-like human neuroblastoma tumor-initiating cells. Proc Natl Acad Sci USA 106: 16805-16810, 2009.
46. Rabbani ZN, Mi J, Zhang Y, Delong M, Jackson IL, Flecenstein K, Salahuddin FK, Zhang X, Clary B, Anscher MS, Vujaskovic Z. Hypoxia inducible factor 1α signaling in fractionated radiation induced lung injury: role of oxidative stress and tissue hypoxia. Radiat Res 173: 165-174, 2010.
47. Raghu G, Weycker D, Edelsberg J, Bradford WZ, Oster G. Incidence and prevalence of idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 174: 810-816, 2006.
48. Selman M, King TE, Pardo A. Idiopathic pulmonary fibrosis: prevailing and evolving hypotheses about its pathogenesis and implications for therapy. Ann Intern Med 134: 136-151, 2001.
49. Sun S, Ning X, Zhang Y, Lu Y, Nie Y, Han S, Liu L, Du R, Xia L, He L, Fan D. Hypoxia-inducible factor-1α induces Twist expression in tubular epithelial cells subjected to hypoxia, leading to epithelial-tomesenchymal transition. Kidney Int 75: 1278-1287, 2009.
50. Swinson DEB, Lones JL, Richardson D, Wykoff C, Turley H, Pastorek J, Taub N, Harris AL, O'Byrne KJ. Carbonic anhydrase IX expression, a novel surrogate marker of tumor hypoxia, is associated with a poor prognosis in non-small cell lung cancer. J Clin Oncol 21: 473-382, 2003.
51. Xia H, Diebold D, Nho R, Perlman D, Kleidon J, Kahm J, Avdulov S, Peterson M, Nerva J, Bitterman P, Henke C. Pathological integrin signaling enhances proliferation of primary lung fibroblasts from patients with idiopathic pulmonary fibrosis. J Exp Med 205: 1659-1672, 2008.
52. Xia H, Khalil W, Kahm J, Jessurun J, Kleidon J, Henke CA. Pathologic caveolin-1 regulation of PTEN in idiopathic pulmonary fibrosis. Am J Pathol 176: 2626-2637, 2010.
53. Xia H, Seeman J, Hong J, Hergert P, Bodem V, Jessurun J, Smith K, Nho R, Kahm J, Gaillard P, Henke C. Low α2β1 integrin function enhances the proliferation of fibroblasts from patients with idiopathic pulmonary fibrosis by activation of the β-catenin pathway. Am J Pathol 181: 222-233, 2012.
54. Yang IV, Luna L, Coldren CD, Fingerlin T, Leach S, Murphy E, Lin J, Cosgrove GP, Lynch DA, Groshong SD, Brown KK, Schwarz MI, Schwartz DA. Genes and miRNAs associated with severity of lung function impairment in idiopathic interstitial pneumonias. Am J Respir Crit Care Med 183: A3559, 2011.
55. Zhang Z, Sun H, Dai H, Walsh RM, Imakura M, Schelter J, Buchard J, Dai X, Chang AN, Diaz RL, Marszalek JR, Bartz SR, Carleton M, Cleary MA, Linsley PS, Grandori C. MicroRNA miR-210 modulates cellular response to hypoxia through the MYC antagonist MNT. Cell Cycle 8: 2756-2768, 2009.